We raise our target price for Remedy to EUR 19.0 (was 17.0 EUR) but because of the rise in the share price, we revise our recommendation to Accumulate (was Buy). The release of Control Resonant as early as 2026 came as a positive surprise compared to our expectations, and we have updated our assumption for the game's release to the end of Q2'26 (was H1’27). The upcoming Control sequel is a critical release for Remedy's investment case, and we are confident in its success. The initial reception of the game's trailer on various platforms also appears promising. We believe that the upcoming game release will support Remedy's shares over the next year, and we find the valuation otherwise still moderate relative to the company's long-term potential.